Poolbeg Pharma
POLB · AIM · Health Care · mcap £46m · 6.4p
Poolbeg develops medicines for cancer immunotherapy-induced cytokine release syndrome (POLB 001) and an oral GLP-1 delivery technology for obesity. It aims to partner or commercialise these assets and holds patents and FDA Orphan Drug Designation for POLB 001.
| Target | Promise | Said | Status |
|---|---|---|---|
| 2024 | |||
| 2024 | Complete lab validation of AI-identified influenza drug targets | 26 Oct 2023 | ⏱ Overdue – no update |
|
Status so far
The deadline has passed; no announcement since says whether it was met. We check again as new reports come in. |
|||